论文部分内容阅读
目的:探讨BPH患者组织学前列腺炎与PSA、前列腺体积、PSA密度(PSAD)、IPSS、最大尿流率(Qmax)及残余尿量(PVR)的相关性。方法:手术切除或经尿道前列腺电切术(TURP)治疗的BPH患者673例。按照是否伴有组织学前列腺炎将患者分为两组:A组:BPH伴组织学前列腺炎;B组:BPH不伴有组织学前列腺炎。比较两组患者PSA、前列腺体积、PSAD、IPSS、Qmax及PVR。结果:A组PSA水平为(5.64±2.48)μg/L,前列腺体积(43.66±13.11)ml,PSAD 0.129±0.048,IPSS(24.72±5.39)分,Qmax(6.94±3.23)ml/s,PVR(124.90±49.80)ml;B组PSA水平为(4.97±1.99)μg/L,前列腺体积(40.41±11.44)ml,PSAD 0.123±0.034,IPSS(23.40±6.21)分,Qmax(7.75±3.52)ml/s,PVR(112.73±50.03)ml。A组PSA水平、前列腺体积、IPSS和PVR均明显高于B组(P<0.05);A组Qmax明显低于B组(P<0.05);PSAD两组间差异无统计学意义(P>0.05)。结论:组织学前列腺炎能明显增加患者的PSA水平、前列腺体积、IPSS和PVR,降低患者Qmax。但是组织学前列腺炎与PSAD无关;组织学前列腺炎是影响BPH临床进展的重要因素。
Objective: To investigate the correlation between histopathological prostatitis and PSA, prostate volume, PSA density (PSAD), IPSS, maximal flow rate (Qmax) and residual urine volume (PVR) in BPH patients. Methods: 673 BPH patients underwent surgical resection or transurethral resection of the prostate (TURP). Patients were divided into two groups according to whether they had histological prostatitis: group A: BPH with histological prostatitis; group B: BPH without histological prostatitis. PSA, prostate volume, PSAD, IPSS, Qmax and PVR were compared between the two groups. Results: The PSA level in group A was (5.64 ± 2.48) μg / L, the volume of prostate was (43.66 ± 13.11) ml, PSAD was 0.129 ± 0.048, IPSS was 24.72 ± 5.39, Qmax was 6.94 ± 3.23, 124.90 ± 49.80) ml in group B, 4.97 ± 1.99 μg / L in PSA group, 40.41 ± 11.44 in prostate volume, 0.123 ± 0.034 in PSAD, 23.40 ± 6.21 in IPSS and 7.75 ± 3.52 in control group, s, PVR (112.73 ± 50.03) ml. PSA level, prostate volume, IPSS and PVR in group A were significantly higher than those in group B (P <0.05); Qmax in group A was significantly lower than that in group B (P <0.05); there was no significant difference between PSAD groups ). Conclusions: Histological prostatitis significantly increases PSA level, prostate volume, IPSS and PVR, and decreases Qmax in patients. However, histological prostatitis has nothing to do with PSAD; histological prostatitis is an important factor affecting the clinical progress of BPH.